Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial

Journal of Clinical Oncology

Volumn 28, Issue 34, 2010, Pages 5101-5109

  Palumbo, Antonio ^a   Bringhen, Sara ^a   Rossi, Davide ^a   Cavalli, Maide ^a   Larocca, Alessandra ^a   Ria, Roberto ^a   Offidani, Massimo ^a   Patriarca, Francesca ^a   Nozzoli, Chiara ^a   Guglielmelli, Tommasina ^a   Benevolo, Giulia ^a   Callea, Vincenzo ^a   Baldini, Luca ^a   Morabito, Fortunato ^a   Grasso, Mariella ^a   Leonardi, Giovanna ^a   Rizzo, Manuela ^a   Falcone, Antonietta Pia ^a   Gottardi, Daniela ^a   Montefusco, Vittorio ^a   Musto, Pellegrino ^a   Petrucci, Maria Teresa ^a   Ciccone, Giovannino ^a   Boccadoro, Mario ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; COMPARATIVE STUDY; CONFUSION; CONSTIPATION; DEATH; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAZARD RATIO; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; INFECTIOUS COMPLICATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEURALGIA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SEPSIS; SYNCOPE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VIRUS INFECTION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 78650993336     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.8216     Document Type: Article

References (44)

1. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, version 2.0. IARC CancerBase No. 5. Lyon, France: IARCPress, 2004
2. Alexanian R, Haut A, Khan AU, et al: Treatment for multiple myeloma: Combination chemotherapy with different melphalan dose regimens. JAMA 208:1680-1685, 1969
3. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
4. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials-Myeloma Trialists' Collaborative Group. J Clin Oncol 16:3832-3842, 1998
5. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005 (Pubitemid 41007864)
6. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
7. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831, 2006 (Pubitemid 43363369)
8. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370:1209-1218, 2007 (Pubitemid 47516593)
9. Hulin C, Facon T, Rodon P, et al: Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 Trial. J Clin Oncol 27:3664-3670, 2009
10. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132, 2007 (Pubitemid 350146107)
11. Weber DM, Chen C, Niesvizky R: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142, 2007 (Pubitemid 350146108)
12. Palumbo A, Falco P, Corradini P, et al: Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA - Italian Multiple Myeloma Network. J Clin Oncol 25:4459-4465, 2007 (Pubitemid 350063804)
13. Waage A, Gimsing P, Fayers P, et al: Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 11:1405-1412, 2010
14. Wijermans P, Schafsma M, van Norden Y, et al: Melphalan + prednisone versus melphalan + prednisone + thalidomide induction therapy for multiple myeloma in elderly patients: First interim results of the Dutch cooperative group HOVON. Haematologica 93, 2008 (abstr 128).
15. Waage A, Palumbo AP, Fayers P, et al: MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta-analysis of 1,682 individual patient data from six randomized clinical trials. J Clin Oncol 28:605s, 2010 (suppl; abstr 8130)
16. Palumbo A, Sezer O, Kyle R, et al: International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 23:1716-1730, 2009
17. Palumbo A, Ambrosini MT, Benevolo G, et al: Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 109:2767-2772, 2007 (Pubitemid 46482069)
18. Spencer A, Prince HM, Roberts AW, et al: Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27:1788-1793, 2009
19. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006
20. Barlogie B, Tricot G, Anaissie E, et al: Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030, 2006 (Pubitemid 43357806)
21. Barlogie B, Attal M, Crowley J, et al: Long-term follow-up of autotransplantation trials for multiple myeloma: Update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 28:1209-1214, 2010
22. Mateos MV, Oriol A, Martinez J, et al: A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/ prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years. Blood 114:3, 2009 (abstr 3)
23. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006 (Pubitemid 44264086)
24. Mohty B, El-Cheikh J, Yakoub-Agha I, et al: Peripheral neuropathy and new treatments for multiple myeloma: Background and practical recommendations. Haematologica 95:311-319, 2010
25. Richardson PG, Sonneveld P, Schuster MW, et al: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dosemodification guideline. Br J Haematol 144:895-903, 2009
26. National Cancer Institute: Common Terminology Criteria for Adverse Events, v3.0. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm#ctc-v3.0
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
28. Cox DR: Regression model and life tables. J R Stat Soc B 34:187-220, 1972
29. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
30. Chirlaque MD, Salmerón D, Ardanaz E, et al: Cancer survival in Spain: Estimate for nine major cancers. Ann Oncol 21:iii21-iii29, 2010 (suppl 3)
31. Bassily MN, Wilson R, Pompei F, et al: Cancer survival as a function of age at diagnosis: A study of the Surveillance, Epidemiology and End Results database. Cancer Epidemiol [epub ahead of print on May 11, 2010]
32. Harousseau JL, Avet-Loiseau H, Attal M, et al: Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: Long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 27:5720-5726, 2009
33. Kyle RA, Leong T, Li S, et al: Complete response in multiple myeloma: Clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 106: 1958-1966, 2006
34. Niesvizky R, Richardson PG, Rajkumar SV, et al: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 143:46-53, 2008
35. Mellqvist U-H, Westin J, Gimsing P, et al: Improved response rate with bortezomib consolidation after high dose melphalan: First results of a Nordic Myeloma Study Group randomized phase III trial. Blood 114, 2009 (abstr 530)
36. Sonneveld P, van der Holt B, Schmidt-Wolf IGH, et al: First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood 112, 2008 (abstr 653)
37. Richardson PG, Sonneveld P, Schuster M, et al: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood 110:3557-3560, 2007 (Pubitemid 350159621)
38. McCarthy PL, Owzar K, Stadtmauer EA, et al: Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): Initial report of patient accrual and adverse events. Blood 114, 2009 (abstr 3416)
39. Attal M, Harousseau JL, Marit G, et al: Lenalidomide after autologous transplantation for myeloma: First analysis of a prospective, randomized study of the Intergroupe Francophone Du Myelome (IFM 2005 02). Blood 114, 2009 (abstr 539)
40. Palumbo A, Gay F, Falco P, et al: Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol 28:800-807, 2010
41. Palumbo A, Dimopoulos MA, Delforge M, et al: A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma. Blood 114, 2009 (abstr 613)
42. Richardson PG, Lonial S, Jakubowiak AJ, et al: High response rates and encouraging time-to-event data with lenalidomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma: Final results of a phase I/II study. Blood 114, 2009 (abstr 1218)
43. Zangari M, Guerrero J, Cavallo F, et al: Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Haematologica 93:953-954, 2008 (Pubitemid 351821742)
44. Palumbo A, Rajkumar SV, Dimopoulos MA, et al: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22:414-423, 2008 (Pubitemid 351255436)